Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) surged ~36% after UK approval of Wegovy amid a Nordic biopharma rebound, while the firm repurchased 22.0M B shares (DKK 5.899bn) in a DKK 11.2bn buyback and struck an India fill–finish deal with Shantha Biologics.
Previous Week Recap
- Novo Nordisk Buyback Progress: Novo Nordisk (NOVO_B) launched a MAR buyback on 6 May 2026 for up to DKK 11.2bn B shares. By 26 June it repurchased 22.0M B shares at DKK 268.02 (DKK 5.899bn); treasury B shares: 39.19M (0.9%).
- Wegovy Regulatory Rally Pushes Shares: NOVO_B jumped ~36% after UK approved Wegovy; move coincided with a Q2 2026 Nordic biopharma rebound. Traders: sharp rally, regulatory catalyst, sector tailwind.
- Outsourcing Cartidge Fill–Finish India: Novo Nordisk (NOVO_B) signed an outsourcing deal with Shantha Biologics for cartridge fill–finish manufacturing in India, establishing a local supply arrangement for Novo Nordisk products.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.